(FNOV) FT Cboe Vest U.S. Equity - Ratings and Ratios

Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US33740F8471

FNOV: FLEX Options, S&P 500, Exchange-Traded

The FT Cboe Vest U.S. Equity Buffer ETF - November (FNOV) is an exchange-traded fund that employs a unique investment strategy to provide buffered exposure to the S&P 500 index. Under normal market conditions, FNOV invests substantially all of its assets in FLexible EXchange Options (FLEX Options) that reference the price performance of the SPDR S&P 500 ETF Trust. FLEX Options are customized equity or index option contracts that trade on an exchange, allowing investors to tailor key contract terms such as exercise prices, styles, and expiration dates to suit their needs.

As a non-diversified fund, FNOVs investment strategy is focused on achieving its defined outcome objective, which is to provide investors with a buffered return based on the performance of the underlying S&P 500 index. The funds use of FLEX Options enables it to offer a level of protection against losses, while also capping potential gains. This strategy is particularly appealing to investors seeking to manage risk and volatility in their portfolios.

Analyzing the technical data, we can observe that FNOVs price is currently above its 20-day and 50-day simple moving averages (SMA20 and SMA50), indicating a positive short-term trend. The Average True Range (ATR) is relatively low, suggesting that the funds price is experiencing low volatility. Considering the fundamental data, FNOVs Assets Under Management (AUM) stand at approximately $854.36 million, indicating a sizable investor base.

Based on the technical and fundamental data, our forecast suggests that FNOV is likely to continue its upward trend in the short term, potentially reaching the upper end of its 52-week range. However, investors should be cautious of the funds non-diversified nature and the potential for market volatility. As the S&P 500 index continues to fluctuate, FNOVs buffered return strategy may help mitigate losses, but it may also cap potential gains. We expect FNOVs price to be influenced by the overall market sentiment and the performance of the underlying S&P 500 index.

Additional Sources for FNOV ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

FNOV ETF Overview

Market Cap in USD 854m
Category Defined Outcome
TER 0.85%
IPO / Inception 2019-11-15

FNOV ETF Ratings

Growth Rating 65.4
Fundamental -
Dividend Rating 0.0
Rel. Strength -5.18
Analysts -
Fair Price Momentum 47.92 USD
Fair Price DCF -

FNOV Dividends

Currently no dividends paid

FNOV Growth Ratios

Growth Correlation 3m 93.1%
Growth Correlation 12m 46.1%
Growth Correlation 5y 85.2%
CAGR 5y 10.11%
CAGR/Max DD 5y 0.64
Sharpe Ratio 12m 1.02
Alpha -0.93
Beta 0.520
Volatility 7.27%
Current Volume 15.3k
Average Volume 20d 12.3k
What is the price of FNOV shares?
As of July 01, 2025, the stock is trading at USD 50.11 with a total of 15,256 shares traded.
Over the past week, the price has changed by +1.99%, over one month by +3.19%, over three months by +7.37% and over the past year by +8.77%.
Is FT Cboe Vest U.S. Equity a good stock to buy?
Yes. Based on ValueRay´s Analyses, FT Cboe Vest U.S. Equity (BATS:FNOV) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 65.40 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of FNOV is around 47.92 USD . This means that FNOV is currently overvalued and has a potential downside of -4.37%.
Is FNOV a buy, sell or hold?
FT Cboe Vest U.S. Equity has no consensus analysts rating.
What are the forecasts for FNOV share price target?
According to our own proprietary Forecast Model, FNOV FT Cboe Vest U.S. Equity will be worth about 54 in July 2026. The stock is currently trading at 50.11. This means that the stock has a potential upside of +7.66%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 54 7.7%